Latest Breaking News On - Liver congress - Page 4 : comparemela.com

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™ - Madrigal Pharmaceuticals (NASDAQ:MDGL)

First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data support findings on liver biopsy and

United statesSan antonioBecky taubAlex howarthStephen harrisonPinnacle clinical researchExchange commissionMadrigal pharmaceuticalsRegistration program for the treatmentOxford universityResearch development of madrigalSummit clinical researchMadrigal pharmaceuticals incEuropean associationLiver congressVisiting professor

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioStephen harrisonBecky taubAlex howarthOxford universityExchange commissionResearch development of madrigalRegistration program for the treatmentMadrigal pharmaceuticalsPinnacle clinical researchSummit clinical researchMadrigal pharmaceuticals incEuropean associationLiver congressVisiting professor

Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL s International Liver Congress™ 2023

SOUTH SAN FRANCISCO, Calif., June 21, 2023 Assembly Biosciences, Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today. | June 21, 2023

William delaneyShannon ryanExchange commissionSam brown incCorporate affairsInternational liver congressAlliance managementAssembly bioSecurities exchangeRisk factors in assembly bioAssembly biosciencesEntry inhibitor programAssembly biosciences incAnnual meetingEuropean associationInhibitor program

Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL s International Liver Congress(TM) 2023

Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL s International Liver Congress(TM) 2023
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Bausch health companies incXifaxanr rifaximin clinical researchResearch posters to beSalix pharmaceuticalsInternational liver congressResearch posters to be featuredPresent dataClinical researchLiver congressResearch postersBausch health companiesEuropean association

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023 - Altimmune (NASDAQ:ALT)

Presentation Selected for Best of EASL Summary Slides Altimmune to Host a NASH KOL and Investor Reception on June 22, 2023 GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) Altimmune, Inc. (NASDAQ:ALT), a

Richard eisenstadtStephena harrisonPinnacle clinical researchOxford universityInternational liver congressAltimmune incPresentation selectedInvestor receptionMedical directorAdjunct professorLiver congressMedia contacts